Kabashima K, et al. - Researchers present the results of a 52-week double-blind extension (Part B) of a phase II, 12-week, randomized, double-blind, placebo-controlled study (Part A) that has already demonstrated nemolizumab's (an anti–interleukin-31 receptor A monoclonal antibody) efficacy in improving pruritus, dermatitis, and sleep in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments. In the extension (Part B) study, long-term efficacy and safety of nemolizumab injected subcutaneously every 4 weeks (Q4W) or every 8 weeks (Q8W) was assessed. Nemolizumab, when administered for up to 64 weeks in patients with moderate-to-severe atopic dermatitis inadequately controlled by topical therapy, was found to be successful in producing the desired result and was well-tolerated overall.